ISLAMABAD: The National Accountability Bureau has launched probe into illegal operations of two pharmaceutical firms, operating without proper licensing for last 10 years.
In the first hearing, Joint Secretary Drug Regulatory Authority of Pakistan (DRAP) Mustafa Haider and Director Licensing of the Authority appeared before the senior NAB officials for questioning.
In the hearing, the NAB authorities have asked DRAP officials to produce on January 14 the necessary record regarding licensing, registration and GMP inspection record including name of inspection team.
The NAB authorities have showed their resentment for taking no action by DRAP authorities and registration of drugs allowed for contract manufacturing has not been cancelled by Drug Registration Board.
According to a letter No. 5-3(46)/Proj/A&P/NABHQ/2013/22, the NAB had expressed displeasure over the malpractices and negligence in registration and quality assurance of drug being manufactured by two firms including M/s Scotmann and M/s Werrick.
Both the companies have been found operating without license since December 31, 2004 but the Drug Registration Authority could not take any action against them.
Both the companies were found manufacturing Alpha 2b, Interferon B and Interferon C without fulfilling the prior official procedures.
This drug is approved around the world for the treatment of chronic hepatitis C, chronic hepatitis B, hairy cell leukemia, chronic myelogenous leukemia, multiple myeloma, follicular lymphoma, carcinoid tumor, and malignant melanoma.
Comments
Comments are closed for this article.